Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Brain Neoplasms × eribulin × Clear all

Phase

Status

Completed 2 Withdrawn 1 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Ovarian Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Brain Neoplasms 1

Interventions

Radiosurgery 7 Magnetic Resonance Spectroscopy 5 Temozolomide 4 Trastuzumab 3 pembrolizumab 2 fluciclovine F-18 2 Specimen Handling 2 Magnetic Resonance Imaging 2 Carboplatin 2 Aminolevulinic Acid 2 tucatinib 1 thymoglobulin 1 tepotinib 1 temsirolimus 1 sodium thiosulfate 1 ribociclib 1 pazopanib 1 patritumab deruxtecan 1 palbociclib 1 osimertinib 1 neratinib 1 irinotecan sucrosofate 1 gancotamab 1 gallium Ga 68 dotatate 1 gadoterate meglumine 1 gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate 1 gadobenic acid 1 fluoroacetic acid 1 fludarabine phosphate 1 eribulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03637868 2020-05-06

ERIBRAIN

Institut Paoli-Calmettes

Phase 2 Withdrawn

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡